On March 15, 2018 Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, reported that an abstract highlighting preclinical data on its technology and therapeutic applications has been selected for presentation at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 14-18, 2018 in Chicago, IL (Press release, , 15 15, 2018, View Source [SID1234524825]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation on Tuesday, April 17, 2018, are as follows:

Poster Title: Enhancing Adoptive Cell Therapies Through Exogenous Regulation: Destabilizing Domains For Next-Generation CAR-T
Lead Author: Celeste Richardson, PhD
Session: Adoptive Cell Therapy – Poster Session 3
Abstract #: 3580 / 18
Date & Time: April 17, 2018, from 8:00am-12:00pm CT
Link to Abstract: View Source!/4562/presentation/7518

About Destabilizing Domains

Obsidian uses Destabilizing Domains (DDs) to enable pharmacologic regulation of protein activity for next-generation cell and gene therapies. Obsidian’s DDs are small, fully-human protein domains that confer conditional stability to a fused payload protein. In the absence of a specific small molecule ligand the fusion protein is rapidly degraded, whereas in the presence of the ligand, the fusion protein becomes stable and functional. Obsidian uses this approach to equip engineered cells with controllable functions that can be precisely tuned by the administration of non-immunosuppressive, small molecule medicines that are readily available and dispensed by the treating physician.

Selecta Biosciences has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Selecta Biosciences, 2018, MAR 15, 2018, View Source [SID1234524797]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 15, 2018 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), reported that it will be attending and presenting at the 28th Annual Oppenheimer Healthcare Conference being held on March 20-21, 2018, at The Westin New York Grand Central in New York City. Details of Actinium’s presentation are as follows (Press release, Actinium Pharmaceuticals, MAR 15, 2018, View Source [SID1234524803]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, March 20, 2018
Time: 1:00 PM ET (subject to changes by the conference organizers)
Room: Track 3
Venue: The Westin New York Grand Central Hotel

Management will conduct 1-on-1 meetings with investors during the conference. To arrange a meeting with Actinium please contact, Steve O’Loughlin, Actinium’s Principal Financial Officer at [email protected].

For more information about the conference, please visit the conference website at the following link: Oppenheimer 28th Annual Healthcare Conference.

On March 15, 2018 X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, reported that an abstract highlighting X4P-001, the Company’s CXCR4 antagonist, has been selected for presentation at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 14-18, 2018 in Chicago, IL (Press release, X4 Pharmaceuticals, MAR 15, 2018, View Source [SID1234524826])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These results demonstrate enhanced immune cell activation and lymphocyte infiltration with X4P-001, alone and in combination with the anti-PD-1 immunotherapy pembrolizumab (Keytruda), in the melanoma tumor microenvironment."

Tweet this
Details of the poster presentation on X4P-001 are as follows:

Poster Title: X4P-001, an oral bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma
Author: Robert H.I. Andtbacka, Huntsman Cancer Institute, University of Utah
Session: Immune Response to Therapies 1
Abstract #: 613
Date & Time: Sunday April 15, 2018 1:00 PM – 5:00 PM CT

"We are pleased to present these clinical biomarker data from our ongoing Phase 1b clinical study with X4P-001 in patients with melanoma," said Sudha Parasuraman, MD, Chief Medical Officer of X4 Pharmaceuticals. "These results demonstrate enhanced immune cell activation and lymphocyte infiltration with X4P-001, alone and in combination with the anti-PD-1 immunotherapy pembrolizumab (Keytruda), in the melanoma tumor microenvironment."

About X4P-001-IO in Cancer

X4P-001-IO is an investigational selective, oral, small molecule inhibitor of CXCR4 (C-X-C receptor type 4) that regulates the tumor microenvironment thereby enhancing endogenous anti-tumor responses. CXCR4 is a chemokine receptor that modulates immune function and angiogenesis through the trafficking of key immune cells such as T- cells, dendritic cells, and myeloid derived suppressor cells. CXCR4 signaling is disrupted in a broad range of cancers, facilitating tumor growth by allowing cancer cells to evade immune detection and creating a pro-tumor microenvironment. X4P-001-IO is being investigated in three separate clinical studies in solid tumors.

On March 28, 2018 Arcus Biosciences (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, reported that five abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2018 Annual Meeting to be held April 14-18, 2018 in Chicago, Illinois. The presentations at AACR (Free AACR Whitepaper) cover three of our clinical and preclinical product candidates including our dual adenosine receptor antagonist, AB928; our PD-1 antibody, AB122; and our small molecule CD73 inhibitor, AB680 (Press release, Arcus Biosciences, MAR 15, 2018, View Source [SID1234525079]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data to be presented include:

AB928:
Title: Pharmacokinetic-Pharmacodynamic relationship for AB928, a dual antagonist of the A2aR and A2bR adenosine receptors – abstract #3769

Title: Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control – abstract #5556

AB122:
Title: Preclinical characterization of GLS-010 (AB122), a fully human clinical-stage anti-PD-1 antibody – abstract #4561

AB680:
Title: CD73 inhibitors (CD73i) reverse the AMP/adenosine-mediated impairment of immune effector cell activation by Immune Checkpoint Inhibitors (ICI) – abstract #710

Title: Discovery and characterization of AB680, a potent and selective small-molecule CD73 inhibitor for cancer immunotherapy – abstract #4886

Additional information – including presentation schedule and full abstracts – can be found at www.aacr.org.